XML 21 R4.htm IDEA: XBRL DOCUMENT v3.24.4
Condensed Consolidated Statements of Operations - USD ($)
 3 Months Ended
Oct. 31, 2024
Oct. 31, 2023
Income Statement [Abstract]    
Net sales $ 115,800,000 $ 151,911,000
Cost of sales 101,284,000 104,029,000
Gross profit 14,516,000 47,882,000
Expenses:    
Selling, general and administrative 51,644,000 32,695,000
Research and development 3,713,000 7,812,000
Amortization of intangibles 6,593,000 5,289,000
Impairment of long-lived assets, including goodwill 79,555,000 0
Proxy solicitation costs 1,583,000 0
CEO transition costs 598,000 0
Total operating expenses 143,686,000 45,796,000
Operating (loss) income (129,170,000) 2,086,000
Other expenses (income):    
Interest expense 9,532,000 4,932,000
Interest (income) and other 635,000 (65,000)
Write-off of deferred financing costs 1,412,000 0
Change in fair value of warrants and derivatives 5,524,000 0
Loss before provision for (benefit from) income taxes (146,273,000) (2,781,000)
Provision for (benefit from) income taxes 2,134,000 (1,344,000)
Net loss (148,407,000) (1,437,000)
Establishment of initial convertible preferred stock purchase option liability 51,179,000 0
Dividend on convertible preferred stock (58,634,000) (1,823,000)
Net loss attributable to common stockholders $ (155,862,000) $ (3,260,000)
Net loss per common share (See Note 6):    
Basic (in dollars per share) $ (5.29) $ (0.11)
Diluted (in dollars per share) $ (5.29) $ (0.11)
Weighted average number of common shares outstanding - basic (in shares) 29,446,000 28,745,000
Weighted average number of common and common equivalent shares outstanding - diluted (in shares) 29,446,000 28,745,000